The rivalry between Novo Nordisk and Eli Lilly has reshaped the pharmaceutical landscape, demonstrating how quickly market leadership can shift in the obesity treatment space. Novo Nordisk’s Wegovy tablet, launched earlier than competitors, currently commands roughly 90% of the oral GLP-1 market, according to CEO Mike Doustdar. The company anticipates oral formulations could account for up to half of the total GLP-1 market by 2030. Danske Bank recently reinforced this outlook, favoring Novo Nordisk in the U.S. pill market due to its earlier entry and demonstrated efficacy.
Eli Lilly’s Zepbound, however, has rapidly gained ground, securing the first European approval in the U.K. and offering dosing flexibility without food or water restrictions. The competition extends beyond market share, with both companies engaged in legal disputes over advertising claims regarding their products’ effectiveness. Analysts note that even leading firms cannot rely on a single blockbuster indefinitely, as demonstrated by Novo Nordisk’s initial dominance giving way to Lilly’s subsequent gains.
While GLP-1 therapies dominate current attention, major pharmaceutical companies are already positioning for the next wave of innovation. Johnson & Johnson has committed $785 million in upfront payments and investments to Sail Biomedicines, with an additional $2.58 billion option to acquire the biotech firm. The partnership focuses on in-vivo CAR-T cell therapies for autoimmune diseases, a shift from traditional CAR-T applications in oncology. This approach aims to bypass logistical challenges by genetically modifying T-cells directly within the patient, potentially reducing costs and scalability barriers associated with ex-vivo CAR-T treatments.
The strategic pivot reflects a broader industry trend. International pharmaceutical firms have announced over $500 billion in U.S. investments, according to Reuters data. Johnson & Johnson plans to increase its U.S. investments by 25% to $55 billion, while Novartis earmarks $23 billion for 10 sites and Gilead Sciences raises its planned investments to $32 billion. These expenditures span production capacity, research, and new therapy platforms, underscoring the sector’s aggressive expansion.
Gilead’s recent performance highlights the challenges even established players face. The company reported a 10% revenue increase to $7.8 billion in early August but cited acquisition-related costs as a drag on earnings. Its existing cell therapy revenues declined 14% year-over-year to $417 million in Q2, reflecting the competitive pressure on current-generation treatments. Despite this, Gilead continues investing in next-generation platforms, mirroring Johnson & Johnson’s long-term strategy.
Mesoblast presents an early commercial success in the cell therapy space with Ryoncil, an FDA-approved allogeneic cell product generating $115 million in net revenue for fiscal 2026, including $36 million in Q4. Unlike personalized CAR-T therapies, Mesoblast’s off-the-shelf approach avoids patient-specific manufacturing, offering potential scalability advantages. The company has also met enrollment targets for a Phase III study of rexlemestrocel-L in chronic lower back pain, with top-line data expected in mid-2027. Success in expanding indications will determine whether Mesoblast can transition from a single product to a broader therapeutic platform.
